Christine Brennan, Ph.D.

Christine Brennan, Ph.D. is a Managing Director at Vertex Ventures HC. Christine has over 15 years in the life-science industry including business development, corporate strategy and venture investing. She was formerly Partner at MRL Ventures Fund from 2017-2021 where she was on the board of Alector, Inc. [NASDAQ:ALEC], Entrada Therapeutics [NASDAQ:TRDA], Tallac Therapeutics and Therini Bio. She was also an observer on the boards of Adagio [NASDAQ:ADGI], LifeMine Therapeutics, PAQ Therapeutics and Translate Bio [NASDAQ:TBIO].

Prior to MRL Ventures Fund, she was Principal at the Novartis Venture Fund from 2013-2017 where she was on the board of Altimmune [NASDAQ:ALT] and an observer on the boards of a number of companies including ROX Medical, lnnocrin Pharmaceuticals, Viamet Pharmaceuticals and Quartet Medicine. Prior to Novartis Venture Fund, she was Chief Business Officer at Vitae Pharmaceuticals from 2010-2013. She also held positions in business development and marketing at small and mid-size biopharmaceutical companies. Christine received her Ph.D. in neuroscience from Dartmouth Medical School and was a post-doctoral fellow in developmental neurobiology at the National Institutes of Health.